AMD

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration and diabetic macular edema.

Alvin Liu, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on deep learning and 3D OCT at the ASCRS annual meeting in San Diego.

David Hutton from Ophthalmology Times and Jay Duker talk about wet AMD and the burdens of treatment on patients thanks to the consistent need for follow-ups and more.

Efavirenz boosts cholesterol turnover in retina, brain.

Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.

Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.

Photobiomodulation is an emerging treatment for dry age-related macular degeneration (AMD).

Ophthalmology Times® talked with Allen Chiang, MD, about the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials at this year's ARVO meeting.

Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.

Physician discusses clinical presentations, treatment options for 2 cases.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56.

Therapies to target geographic atrophy are in sight.

In a presentation during the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held at the Ernest N. Morial Convention Center in New Orleans, Luxa Biotechnology offered details of a clinical trial evaluating transplantation of cells derived from adult retinal pigmented epithelium stem cells to treat dry AMD.

According to data presented at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans, post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced geographic atrophy (GA) growth.

Ophthalmology Times® talked with Carl Danzig, MD, FASRS, at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.

According to data presented at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, staggered administration of Ixo-vec in non-human primates showed peak aflibercept protein levels in the second eye within the targeted therapeutic range, supporting the potential for bilateral administration.

SB15 (Samsung Bioepis) has shown similar efficacy, pharmacokinetics, safety, immunogenicity to aflibercept after 56 Weeks in phase 3 clinical trial.

Ophthalmology Times® talked with Deborah Ferrington, PhD, about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

Ophthalmology Times® talked with Roland Mattern, Director of Sales and Marketing for eSight and eSight User Gary Foster at this year's ARVO meeting about eSight Go, the new model of smart glasses for low vision enhancement

The company said this week it plans to open the trial for enrollment this quarter and expects topline results by the third quarter of 2024.

The clearance of the Investigational New Drug Application will allow the company to initiate Phase 2 trials of the drug for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).